Amgen has quietly delivered a strong year in 2026, with shares up roughly 19% year-to-date. The stock touched an all-time intraday high of $398.00 in late July before pulling back modestly. Against that backdrop, the $420 price target has emerged as the next major milestone on Wall Street. UBS raised its target to $420 from $400 in mid-July while maintaining a Buy rating. TD Cowen likewise lifted its target to $420 earlier this year. Goldman Sachs holds a target of $425, and Piper Sandler has set a Street-high target of $427. These targets reflect a growing conviction that Amgen's product transition is working — and that the pipeline, particularly MariTide, is being undervalued.
With a market capitalization of approximately $208 billion, Amgen ranks among the world's largest independent biotechnology companies. The stock trades at a forward price-to-earnings (P/E) ratio of roughly 17, which is relatively modest for a company with its revenue scale and free cash flow generation. Revenue for 2025 reached $36.75 billion, up roughly 10% year-over-year, and management has guided for 2026 total revenues in the range of $37.0 billion to $38.4 billion. The company also carries a 2.6% dividend yield, supported by 14 consecutive years of dividend growth, making it attractive to income-oriented investors. However, the company operates with substantial leverage — approximately $57 billion in debt against $8.8 billion in cash — a factor that merits close attention.
The bull case for AMGN reaching $420 rests on several pillars. First, the newer product portfolio is firing on all cylinders. Repatha, the cholesterol-lowering therapy, posted 34% year-over-year sales growth in Q1 2026, reaching $876 million. Evenity, the osteoporosis treatment, grew 27% to $562 million and now commands 65% of the U.S. bone-builder market. The rare disease segment expanded 25%, led by Uplizna's 188% surge.
Second, and perhaps most consequential, is MariTide — Amgen's experimental obesity and diabetes drug. Unlike weekly injectables from competitors such as LLY and NVO, MariTide is being tested with monthly, every-eight-week, and even quarterly dosing schedules, potentially offering a major convenience advantage. Phase 2 data demonstrated up to 20% weight loss over 52 weeks without a plateau, and multiple Phase 3 trials are now underway. If MariTide succeeds, Amgen could capture a meaningful share of the estimated $100 billion obesity market, transforming its growth profile.
The path to $420 is far from guaranteed. Legacy products Prolia and XGEVA, which together accounted for roughly 21% of 2024 revenue, are facing intensifying biosimilar competition following the loss of exclusivity. Combined revenue from these drugs fell 32% year-over-year in Q1 2026. Meanwhile, Tavneos — a rare-disease drug acquired through the Horizon Therapeutics deal — faces serious regulatory headwinds. The FDA has proposed withdrawing Tavneos from the U.S. market over concerns about manipulated clinical trial data, the EMA has recommended revoking its European authorization, and a pivotal study was retracted from the New England Journal of Medicine.
Additionally, Amgen's debt load of $57.4 billion, largely tied to the Horizon acquisition, limits balance sheet flexibility. Any macroeconomic downturn, unexpected pipeline setback, or accelerated biosimilar erosion could weigh on sentiment and delay the march toward $420.
The analyst community remains divided but leans constructive. Of the 34 analysts covering AMGN, roughly 14 rate it a Buy or equivalent, 17 rate it Hold, and 3 recommend Sell. The average 12-month price target sits at approximately $357, reflecting a modest downside from current levels, but the dispersion is wide — ranging from a bearish $180 to an optimistic $476. Notably, the most bullish targets cluster around the $420–$427 range, suggesting that while the consensus is cautious, several influential firms see a clear path higher. Recent upward revisions from UBS, TD Cowen, and Goldman Sachs indicate that momentum among the bulls is building.
From a technical perspective, AMGN has carved a steady uptrend throughout 2026, with higher lows forming near $337 in June, $346 in late June, and support building in the $370 zone during July. The 52-week high of $398.00 represents immediate overhead resistance. A decisive breakout above $398–$400 on above-average volume would likely open the door to the $420 target zone. On the downside, a breach of the $370 support area would call the near-term uptrend into question and potentially shift focus back toward the $350 region, where multiple analysts have set their price targets.
Navigating a stock like Amgen requires staying ahead of rapidly changing market conditions, and that is where Tickeron's AI Daily Buy/Sell Signals can add value. This tool uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on real-time technical behavior, trend analysis, and AI-driven pattern recognition. For traders tracking whether AMGN can build momentum toward $420 or whether resistance near $398 will hold, these signals offer a data-driven way to identify shifting trends without constant manual chart-watching. Whether you are looking for new opportunities or managing an existing position, AI Daily Buy/Sell Signals can help streamline your decision-making process.
The question of whether Amgen can reach $420 is neither a stretch nor a certainty. The stock sits roughly 9% below that level, which is a realistic gap that could be closed over a reasonable time frame if the right catalysts materialize. The strongest arguments in favor include the accelerating growth of Repatha, Evenity, and the rare disease portfolio, combined with the enormous optionality embedded in MariTide. The forward P/E of approximately 17 also leaves room for multiple expansion if sentiment improves. However, biosimilar headwinds, the Tavneos overhang, and Amgen's substantial debt burden are genuine obstacles that cannot be dismissed. Investors should watch the upcoming Q2 2026 earnings report, MariTide Phase 3 enrollment updates, and the stock's ability to break decisively above the $398–$400 resistance zone as key milestones on the journey to $420.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, AMGN has been loosely correlated with BIIB. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGN jumps, then BIIB could also see price increases.
| Ticker / NAME | Correlation To AMGN | 1D Price Change % | ||
|---|---|---|---|---|
| AMGN | 100% | +1.51% | ||
| BIIB - AMGN | 62% Loosely correlated | +0.80% | ||
| PFE - AMGN | 52% Loosely correlated | +2.14% | ||
| GILD - AMGN | 52% Loosely correlated | +1.80% | ||
| MRK - AMGN | 50% Loosely correlated | +0.16% | ||
| ABBV - AMGN | 47% Loosely correlated | +0.89% | ||
More | ||||